Literature DB >> 24099959

Incidence of cancer in a cohort of Spanish patients with systemic lupus erythematosus.

Ana Hidalgo-Conde1, Manuel de Haro Liger, Manuel Abarca-Costalago, Martina Álvarez Pérez, Pedro Valdivielso-Felices, Pedro González-Santos, Antonio Fernández-Nebro.   

Abstract

OBJECTIVE: To determine the incidence and prevalence of cancer in a cohort of patients with systemic lupus erythematosus (SLE) and identify associated risk factors. PATIENTS AND METHODS: The study comprised a dynamic cohort of SLE patients (November 1989 to December 2006) at a tertiary referral centre. An adjusted external control from the hospital tumour registry was used.
RESULTS: The study included 175 SLE patients (90% women), with a mean time at risk of 1370.5 patient-years. Fourteen women (8%) died, mainly from cardiovascular events. No patient died due to malignancy. We found 35 tumours in 28 patients, 25 of them after the diagnosis of SLE, of which 5 were malignant. The rate of benign tumours was 14.6/1000 patient-years (95% CI, 8.9-22.5) and of malignant tumours 3.6/1000 patient-years (95% CI, 1.5-8.8), with a crude incidence odds ratio for malignant tumours of 3.5 (95% CI, 1.5-7.9). However, this significance was lost after standardizing the rates. Concerning associated risk factors, differences were found in the mean erythrocyte sedimentation rate [HR 1.4 (1.1-1.7)], and the presence of thrombosis [HR 6.9 (1.49-41.2)], especially arterial thrombosis.
CONCLUSIONS: We found a crude incidence rate of cancer that was almost four times greater in our SLE patients as compared with the expected rate in the hospital area of western Malaga.
Copyright © 2012 Elsevier España, S.L. All rights reserved.

Entities:  

Keywords:  Cancer; Cáncer; Incidence; Incidencia; Lupus eritematoso sistémico; Malignancy; Malignidad; Systemic lupus erytematosus

Mesh:

Year:  2013        PMID: 24099959     DOI: 10.1016/j.reuma.2012.10.015

Source DB:  PubMed          Journal:  Reumatol Clin        ISSN: 1699-258X


  4 in total

1.  Systemic lupus erythematosus and malignancies risk.

Authors:  Song Mao; Hua Shen; Jianhua Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2015-08-29       Impact factor: 4.553

Review 2.  A review on SLE and malignancy.

Authors:  May Y Choi; Kelsey Flood; Sasha Bernatsky; Rosalind Ramsey-Goldman; Ann E Clarke
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-10       Impact factor: 4.098

3.  No association between the risk of breast cancer and systemic lupus erythematosus: evidence from a meta-analysis.

Authors:  Zahra Rezaieyazdi; Samira Tabaei; Yalda Ravanshad; Javad Akhtari; Hassan Mehrad-Majd
Journal:  Clin Rheumatol       Date:  2018-01-02       Impact factor: 2.980

4.  Diagnostic Dilemma of Paraneoplastic Rheumatic Disorders: Case Series and Narrative Review.

Authors:  Youngmin Cho; Erik W Anderson; Sara J Guevara; Santiago J Miyara; Naomi Maria; Christine N Metz; Stefanos Zafeiropoulos; Dimitrios Giannis; Jifeng Wang; Oluseyi Abidoye; James M Mumford; Judith Aronsohn; Ernesto Molmenti; Huma Sohail
Journal:  Cureus       Date:  2021-11-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.